The minimum information about proteomics experiment (MIAPE)
Article Abstract:
The principles underpinning the development of the guidance modules and the ramifications of various interest groups such as experimentalists, funders, publishers and the private sector are discussed. The criticality of appropriate tools and resources in enabling the minimum information about proteomics experiment (MIAPE)-compliant reporting is illustrated.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2007
User Contributions:
Comment about this article or add new information about this topic:
The minimum information about proteomics experiment (MIAPE)
Article Abstract:
The principles underpinning the development of the guidance modules and the ramifications of various interest groups such as experimentalists, funders, publishers and the private sector are discussed. The criticality of appropriate tools and resources in enabling the minimum information about proteomics experiment (MIAPE)-compliant reporting is illustrated.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2007
User Contributions:
Comment about this article or add new information about this topic:
Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides
Article Abstract:
Mass spectrometry and liquid chromatography analysis are utilized to examine protein processing.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2003
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: The Chromaline Corporation (CMLH). Polymer Research Corporation of America (PROA). JLM Industries, Inc. (JLMI)
- Abstracts: The information challenge. A chink in our armour? Look up from the ledger
- Abstracts: Scaling the biobusiness information mountain. Budding actors in mammalian G-protein signaling. Biobusiness on the web
- Abstracts: Fingerprinting the circulating repertoire of antibodies from cancer patients. The rollercoaster ride to anti-cancer antibodies